Claims for Patent: 8,633,309

Summary for Patent: 8,633,309

Title:	Nucleoside phosphoramidates
Abstract:	Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Inventor(s):	Ross; Bruce (El Granada, CA), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (San Ramon, CA), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (San Jose, CA), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Totowa, NJ)
Assignee:	Gilead Pharmasset LLC (Foster City, CA)
Application Number:	13/738,425
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,633,309
Patent Claims:	1. A compound represented by the formula (4): ##STR00037## wherein P* represents a chiral phosphorus atom and wherein the compound is at least 97% of the S.sub.Pstereoisomer represented by the formula (S.sub.P-4): ##STR00038## and not more than 3% of the R.sub.Pstereoisomer represented by the formula (R.sub.P-4): ##STR00039## 2. The compound according to claim 1, wherein the compound is at least 98% of the S.sub.Pstereoisomer represented by the formula (S.sub.P-4) and not more than 2% of the R.sub.Pstereoisomer represented by the formula (R.sub.P-4). 3. The compound according to claim 1, wherein the compound is at least 99% of the S.sub.Pstereoisomer represented by the formula (S.sub.P-4) and not more than 1% of the R.sub.Pstereoisomer represented by the formula (R.sub.P-4). 4. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable medium. 5. A pharmaceutical composition comprising the compound according to claim 2 and a pharmaceutically acceptable medium. 6. A pharmaceutical composition comprising the compound according to claim 3 and a pharmaceutically acceptable medium. 7. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 1. 8. The method according to claim 7 further comprising administering to the human another antiviral agent. 9. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 2. 10. The method according to claim 9 further comprising administering to the human another antiviral agent. 11. A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 3. 12. The method according to claim 11 further comprising administering to the human another antiviral agent.